3933 — United Laboratories International Holdings Share News
0.000.00%
- HK$14.32bn
- HK$8.41bn
- CNY13.21bn
Brief: United Laboratories International Enters Up To Hk$1.1 Bln Term Loan Facility Agreement
Brief: United Laboratories International Says Unit Received Notice Of Approval Of Clinical Trial
Brief: United Laboratories International Says Applications For Clinical Trial Of Class-1 New Drug Tul01101 Ointment Applied Approved By NMPA
Brief: United Laboratories International Says Sodium Hyaluronate Eye Drops Approved For Marketing
HK-listed United Laboratories drops most in 9 mths on flat H1 profit growth
Brief: United Laboratories International Posts HY Profit Attributable RMB629.5 Mln
Brief: United Laboratories International Says Unit Got Notice On Acceptance Of Clinical Trial Registration Issued By China's Nmpa About Semaglutide Injection
Brief: United Laboratories International Says Co As Borrower Entered Into Facility Letter
Brief: United Laboratories International Says Unit And Muyuan Foods Co Entered Into Shareholders' Agreement
Brief: United Laboratories International Says To Borrow HK$300 Mln From China Minsheng Bank HK Branch
Brief: United Laboratories International Entered Into Facility Letter With Industrial Bank Hk Branch
Brief: United Laboratories International - Got Notice On Acceptance Of Clinical Trial From Nmpa Regarding Insulin Degludec And Insulin Aspart Injection.
Brief: United Laboratories International Says FY Profit Attributable RMB988.1 Mln
Brief: United Laboratories International Sees FY Profit Of RMB980 Mln
Brief: United Laboratories Enters Loan Facility Agreement With China Everbright HK Branch Of Up To HK$200 Mln
Brief: United Laboratories International Entered Facility Letter With Chiyu Banking Corp
Brief: United Laboratories International Entered Facility Letter With Bank Of China (Hong Kong) For Term Loan Facility Up Of HK$200 Mln
Brief: United Laboratories International Says HY Profit Attributable RMB623.1 Mln
Brief: United Laboratories International Sees HY Net Profit Of About RMB600 MLN